Our study has identified the potential for the HDAC inhibitors mocetinostat, CUDC-101, and pracinostat in enhancing the efficacy of radiotherapy in the treatment of HNSCC models through the suppression of the repair of DNA DSBs. The gene discussed is HDAC9; the disease is head and neck squamous cell carcinoma.